Navigation Links
Verenium Announces Debt Repurchase
Date:3/11/2011

SAN DIEGO, March 11, 2011 /PRNewswire/ -- Verenium Corporation (Nasdaq: VRNM), a leading industrial biotechnology company focused on the development and commercialization of high-performance enzymes, today announced that it repurchased $28.4 million in principal amount of its outstanding convertible notes in a series of privately-negotiated transactions.

As part of these transactions, the Company repurchased $19.9 million in principal amount of its 5.5% Notes and $8.5 million in principal amount of its 9% Notes, leaving an aggregate of $46.3 million in principal amount of 5.5% and 9% Notes outstanding. To effect this repurchase, the Company paid a total of $27.6 million in cash to a group of institutional investors, excluding accrued interest as of the closing date.  The Company has repurchased $49.4 million in convertible notes since September 2010.

"We are very pleased to have completed these repurchases, and believe this is another important step in creating a capital structure that supports the continued growth and success of Verenium as we focus on building the next leading industrial enzymes company," said Jeffrey Black, Senior Vice President and Chief Financial Officer Designate at Verenium. "We believe that we have now reduced our debt to a more appropriate level for the Company given our size and stage of development."  

About VereniumVerenium, an industrial biotechnology company, is a global leader in developing high-performance enzymes.  Verenium's tailored enzymes are environmentally friendly, making products and processes greener and more cost-effective for industries, including the global food and fuel markets.  Read more at www.verenium.com.

Forward-Looking StatementsStatements in this press release that are not strictly historical are "forward-looking" and involve a high
'/>"/>

SOURCE Verenium Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Worlds Largest Soybean Processing Industrial Complex Converts Half of Capacity to Usage of Vereniums Purifine® PLC Enzymatic Degumming Process Engineered and Installed by Alfa Laval
2. Verenium Corporation to Announce Fourth Quarter and Year-End 2010 Financial Results
3. Verenium to Present at Jefferies 11th Global Clean Technology Conference
4. Verenium Announces Favorable Outcome of Capital Ventures International Lawsuit
5. Verenium to Present at Piper Jaffray Sixth Annual Clean Technology & Renewables Conference
6. Verenium Reports Financial Results for the Third Quarter 2010
7. Verenium to Present at Jefferies 10th Global Clean Technology Conference
8. Verenium and Alfa Laval Announce Extension of Purifine® PLC Enzyme Agreement
9. Verenium Announces Regulatory Approval for Purifine® PLC in China
10. Verenium Launches DELTAZYM® GA L-E5 Enzyme for Fuel Ethanol Production
11. Verenium Appoints Kevin Bracken Vice President of Manufacturing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2015)... , May 21, 2015 ... inner feelings - and those of others. Being able ... senses. Analyze and read people to anticipate their thoughts ... your deepest emotions and feelings to create unique abstract ... of responsive games. Get inside a first-person-shooter as it ...
(Date:5/21/2015)... Bridgewater, NJ (PRWEB) May 21, 2015 ... and a method for diagnostic or therapeutic imaging within ... the apparatus uses an endoscope having a low cost, ... original USPTO filing date was October 18, 2013 and ... The technology enables the physician to customize the ...
(Date:5/21/2015)... SURPRISE, ARIZ. (PRWEB) May 21, 2015 ... E. Webb Medical Center (BDWMC), Sun Health Foundation funded ... medical center’s new inpatient pharmacy with the most up-to-date ... to open June 2. The pharmacy's 45 staff members ... much larger 4,895-square-foot space in the coming days. ...
(Date:5/21/2015)... , May 21, 2015 /PRNewswire/ - RepliCel ... clinical stage regenerative medicine company focused on the ... upcoming poster presentation at the International Society for ... for chronic Achilles tendinosis currently in a Phase ... May 29 th from 5:30 PM to ...
Breaking Biology Technology:5 Days to Meet ARGUS - The World's First Contactless Emotions Scanner 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 2IpAuctions™ Presents The Worlds Smallest Disposable Illuminated Endoscope For Auction 3Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 2Sun Health Foundation Provides $3.25M to Expand, Relocate Banner Del E. Webb Medical Center Pharmacy 3RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 2RepliCel to Present Unique Autologous Cell Treatment for Achilles Tendinosis at International Society for Cellular Therapy Conference 3
... Dec. 13 /PRNewswire-FirstCall/ - MIGENIX Inc.,(TSX: MGI; ... for infectious,diseases, reports financial results for the ... update on its programs., UPDATE ON ... (Omigard(TM)/CPI-226/MX-226; topical cationic peptide;,prevention of catheter-related infections): ...
... 13 Ten new validation studies,were published during ... bringing the total number of studies published to ... considerable increase in interest from US and,European institutes" ... world,s,most highly respected academic medical institutions and teaching ...
... Neurocrine Biosciences,Inc. (Nasdaq: NBIX ) announced today that ... Drug Administration (FDA) indicating,that the New Drug Application (NDA) ... treatment of insomnia is approvable pending additional clinical and,preclinical ... an action letter from the FDA,stating that indiplon 5 ...
Cached Biology Technology:MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 2MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 3MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 4MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 5MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 6MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 7MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 8MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 9MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 10MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 11MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 12MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 13MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 14MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 15MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 16MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 17MIGENIX Reports Second Quarter Fiscal Year 2008 Financial Results 182007 a "Record Year" for Successful Validation Studies of Simbionix Simulators 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 2Neurocrine Receives Approvable Letter for Indiplon Capsules with Additional Safety and Efficacy Data Required by FDA 3
(Date:5/21/2015)... 21, 2015 According to ... Solutions (Hardware, Software, Services), by Applications (Surveillance (Airborne, ... by End-Users (Military & Defense & Commercial) - ... Imaging Market is expected to grow from $7252.0 ... at a Compound Annual Growth Rate (CAGR) of ...
(Date:5/20/2015)... NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... 3D-ID LLC, a company engaged in biometric identification is ... technology portion of the recently awarded TIES (Technical Information ... the Army. 3D-ID LLC has a suite ... enforcement and security agencies. Gino Pereira ...
(Date:5/19/2015)... 19, 2015 Research ... addition of the  "Genetic Testing Market Outlook ... http://photos.prnewswire.com/prnh/20130307/600769) , ,A recent report, Genetic Testing ... of the current and future genetic testing ... their working principles and types are covered ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 2NXT-ID, Inc Announces Participation as Member of Team Battelle for TIES Contract Award 3Global Genetic Testing Market Outlook 2018 2
... The body is a battle zone. Cells constantly compete with ... some cells win this competition is well known to be the ... space and survival is not as clear. A study on fruit ... by Johns Hopkins researchers describes how stem cells win this battle ...
... CORVALLIS, Ore. According to an analysis of statewide data ... $50,000 a year were more than three times likely to ... their insurance status during pregnancy and delivery. In ... likely among mothers with Medicaid coverage, and four times more ...
... the Natural History Museum believe that carnivorous behaviour in plants ... grown plants such as petunias at least part ... Victorian Gothic, Darwin and modern insights into vegetable carnivory, is ... of the Linnean Society . Carnivorous plants have caught ...
Cached Biology News:Stem cells battle for space 2Lower income women report more insurance-based discrimination during pregnancy, delivery 2Scientists think 'killer petunias' should join the ranks of carnivorous plants 2
Mouse polyclonal antibody raised against a partial recombinant CSRP3. NCBI Entrez Gene ID = 8048...
... raised against a partial recombinant ... SLC22A3 (NP_068812, 90 a.a. ... protein with GST tag. ... NM_021977 Protein ...
... UniPrimer-fluorescein is a hairpin primer labeled ... (fluorescein and non-fluorescent quencher) and a ... UniPrimer is identical to the UniPrimer ... System (S7901) and is provided at ...
... clear polystyrene with frosted labeling surfaces, ... cell counting. 100% integrity tested. Linkage: ... product number, created to easily match ... availability yet, please order under the ...
Biology Products: